The Pituitary Society present results from survey on COVID-19 vaccine and adrenal insufficiency
In preparation for the upcoming COVID-19 vaccine, The Pituitary Society surveyed its membership to understand planned approaches to glucocorticoid management in patients with adrenal insufficiency, who will receive the vaccine.
They have received the results of the survey from 103 responders:
Thirty six percent of clinicians plan to recommend that patients automatically increase their glucocorticoid dosage with administration of the first vaccine injection. Of these, 71% plan to increase the glucocorticoid dose on the day of the vaccine, and 40% plan to increase the glucocorticoid dose prior to the vaccine. In contrast, 64% do not plan to recommend an automatic glucocorticoid dose increase with vaccine administration. Of this group, 93% plan to increase the dose if the patient develops a fever following administration, and 55% plan to increase the dose if myalgias and arthralgias occur.
These survey results offer a glimpse into the planned approach of our members for glucocorticoid management in patients with adrenal insufficiency. This survey does not reflect results of a trial on efficacy of glucocorticoid management in patients receiving the vaccine, nor the impact of a particular glucocorticoid dose on the vaccine immune response.
Importantly, these results do offer suggested management guidance based on responses from experienced clinicians treating pituitary diseases worldwide.
Find out more.